Menu Report

Long-Term Health and Economic Effects of Antimicrobial Resistance
Date: 5-8 January 2021
Register: here

The main topics for this meeting are:

  • The product pipeline for new antibiotics and related medical products, including diagnostics and
    antimicrobial stewardship in medicine and animal agriculture.
  • Speakers will discuss the economic challenges of bringing new antibiotics to market, including financial difficulties of the post-market phase, as well as various proposals to strengthen the drug pipeline, and the relationship between the medicines and diagnostics markets.
  • Other speakers will address the unique challenge of developing and interpreting veterinary diagnostic tests.
  • The next group of speakers will discuss antimicrobial stewardship, particularly in challenging settings such as nursing homes, rural and remote areas, and low- and middle-income countries, as well as the challenges and incentives for stewardship in animal agriculture.
  • The final set of speakers will present information about the Global Research on Antimicrobial Resistance study and the human factors that drive resistance.

The future of the foodservice sector in Europe: A roadmap beyond Covid-19
Date: 27 January 2021
Register: here

The ongoing health crisis is having a devastating impact on Europe’s restaurants, cafés and bars. Join this EURACTIV Virtual Conference to discuss what the optimal blueprint for the future of the foodservice industry might look like in Europe and what mix of policy tools can be most helpful to the sector.

Tackling cancer comorbidities
Date: 24 February 2021
Register: here

Key questions:
• Does the Commission’s cancer plan do enough to address the comorbidities and side effects of cancer and its treatment?
• Do we have enough quality data and research to understand the full picture of cancer comorbidities and side effects? If not, what needs to change and what tools or existing funds are available?
• Can complications are prevented? How can we ensure more effective treatments for cancer patients with comorbidities (real-world data, clinical trial diversity, etc.)?
• Can cancer treatment optimization and tumour boards better take into account side effects and co-morbidities? Do doctors have the right information and knowledge to do so?
• How can long-term care for survivors be improved when it comes to late effects/comorbidities?